Skip to main content
. 2017 Aug 29;7:9793. doi: 10.1038/s41598-017-09470-0

Figure 4.

Figure 4

Serelaxin decreased kidney inflammation. Quantitative real-time PCR (qRT-PCR) analysis showed that treatment with serelaxin prevented the increases in the inflammatory markers (a) IL-1-β, (b) IL-6, (c) ICAM-1, (d) VCAM-1, (e) MCP-1, and (f) NFκB mRNA. Serelaxin also prevented the increases in (g) CD68 immunostaining and (h) phospho-NFκB protein abundance in the kidney. Equal protein loading was verified by using an anti-β-actin antibody. The detection was executed by an ECL western blotting analysis system. Whole bolts are reported in Supplemental Fig. 1. Results are expressed as means ± SEM (n = 6 rats for qRT-PCR, n = 3 for western blot). Statistical analysis was performed with one-way ANOVA.